Top Suppliers:I want be here


88191-84-8

88191-84-8 structure
88191-84-8 structure

Name Z-Val-Phe-H
Synonyms CARBOBEZOXY-VALINYL-PHENYLALANINALZ-VAL-PHE-CHO
MFCD00798796
Carbamic acid, N-[(1S)-1-[[[(1S)-1-formyl-2-phenylethyl]amino]carbonyl]-2-methylpropyl]-, phenylmethyl ester
Carbamic acid, N-[(1S)-1-formyl-2-phenylethyl]-, phenylmethyl ester
N-benzyloxycarbonyl-(S)-valinylphenylalaninal
benzyl [(2S)-1-oxo-3-phenylpropan-2-yl]carbamate
Benzyl [(2S)-3-methyl-1-oxo-1-{[(2S)-1-oxo-3-phenylpropan-2-yl]amino}butan-2-yl]carbamate
Z-Val-Phe-H
Z-VAL-PHE-CHO
(S)-(-)-2-(Benzylcarbonylamino)-3-phenylpropanal
Z-L-Val-L-Phe-OH
Benzyl [(2S)-1-oxo-3-phenyl-2-propanyl]carbamate
CARBOBENZOXY-VALINYL-PHENYLALANINAL
CALPAIN INHIBITOR III
Benzyl [(2S)-3-methyl-1-oxo-1-{[(2S)-1-oxo-3-phenyl-2-propanyl]amino}-2-butanyl]carbamate
Cbz-L-Val-L-Phe-OH
Z-VAL-PHE-ALDEHYDE
MDL 28170
MDL-28170
Description cysteine protease inhibitor of calpain that rapidly penetrates the blood-brain barrier following systemic administration[1][2]. MDL-28170 also block γ-secretase[4].
Related Catalog
Target

Calpain[1].

In Vitro MDL-28170 significantly and time-dependently improves the recovery of synaptic responses in hippocampal slices following prolonged, moderate hypoxia without hypoxic depolarization[1]. MDL-28170 dose-dependently inhibits brain cysteine proteinase activity (in vitro Ki= 0.01 μM)[2].
In Vivo Treatment with MDL-28170 (50 mg/kg, i.p.) completely prevents the striatal damage in four animals in each of the two treatment groups. The numbers of necrotic neurons are reduced by 85% and 68% in animals in which MDL-28170 injections are initiated at 0.5 and 3 h of recirculation, respectively[2]. MDL-28170 (30 mg/kg, i.p.) reduces the functional and structural deterioration of corpus callosum following fluid percussion injury[3]. MDL-28170 (10 mg/kg, i.p.) significantly improves nerve function parameters in diabetic rats. MDL-28170 (3 and 10 mg/kg, i.p.) improves nociceptive behavior in diabetic rats[5].
References

[1]. Chen ZF, et al. Neuronal recovery after moderate hypoxia is improved by the calpain inhibitor MDL28170. Brain Res. 1997 Sep 19;769(1):188-92.

[2]. Li PA, et al. Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. Neurosci Lett. 1998 May 8;247(1):17-20.

[3]. Ai J, et al. Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury. J Neurotrauma. 2007 Jun;24(6):960-78.

[4]. De Strooper B, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999 Apr 8;398(6727):518-22.

[5]. Kharatmal SB, et al. Calpain inhibitor, MDL 28170 confer electrophysiological, nociceptive and biochemical improvement in diabetic neuropathy. Neuropharmacology. 2015 Oct;97:113-21.

Density 1.2±0.1 g/cm3
Boiling Point 450.4±45.0 °C at 760 mmHg
Molecular Formula C22H26N2O4
Molecular Weight 382.45
Flash Point 226.2±28.7 °C
PSA 84.50000
LogP 3.77
Vapour Pressure 0.0±1.1 mmHg at 25°C
Index of Refraction 1.571
Storage condition 2-8℃
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Safety Phrases 22-24/25
RIDADR NONH for all modes of transport
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.